March 29, 2024
Updated May 12, 2025
19 minute read
Medical writing is a specialized field dedicated to producing clear, accurate, and well-structured scientific and medical information for various audiences. This can range from detailed regulatory documents for government agencies to educational materials for patients and promotional content for new therapies. Essentially, a medical writer acts as a crucial bridge, translating complex data and research findings into understandable and actionable content.
The role is both challenging and rewarding, offering a unique blend of scientific understanding and communication artistry. Medical writers are integral to the dissemination of medical knowledge, playing a vital part in the development and launch of new treatments, the education of healthcare professionals, and the empowerment of patients. The ability to convey intricate information with precision and clarity is a hallmark of a successful medical writer.
Introduction to Medical Writing
At its core, medical writing involves the creation and editing of a wide array of documents within the healthcare and pharmaceutical sectors. This includes, but is not limited to, clinical trial reports, manuscripts for scientific journals, regulatory submissions, patient education brochures, and marketing materials for new drugs or medical devices. The primary objective is to communicate complex medical and scientific information in a manner that is not only accurate and clear but also tailored to the specific needs of the intended audience.
u10bhk|
Find a path to becoming a Medical Writer. Learn more at:
OpenCourser.com/career/u10bhk/medical
Reading list
We've selected some books
that we think will supplement your
learning. Use these to
develop background knowledge, enrich your coursework, and gain a
deeper understanding of the topics covered in
Medical Writer.
Known universally across medical schools and fellowship programs as the Hulley and Cummings manual, this fifth edition guides investigators through formulating FINER research questions, cohort and randomized designs, sample size estimation, and IRB ethics.
Establishes the foundational philosophy of preventive medicine, contrasting the high-risk individual approach with the population strategy. Explains why shifting average community risk factor distributions prevents far more disease burden than treating extreme clinical outliers alone.
Sets the gold standard for rigorous observational risk factor research, detailing sufficient-component cause models, confounding control, effect measure modification, and quantitative bias analysis. Indispensable for graduate epidemiologists designing and critiquing etiologic studies.
Serving as the gold-standard reference on randomized controlled trial methodology, Friedman, Furberg, DeMets, Reboussin, and Granger detail blinding, covariate-adaptive randomization, interim Data Monitoring Committees, and intent-to-treat analysis.
Originating from the flagship National Institutes of Health (NIH) Clinical Center training course, Gallin, Ognibene, and Johnson synthesize regulatory FDA IND filings, Good Clinical Practice (GCP), biostatistics, and translational protocol management.
Demystifies health risk statistics for clinicians, students, and patients by distinguishing absolute risk from misleading relative risk ratios. Equips readers with concrete tools to interpret disease probabilities, screening trade-offs, and baseline mortality tables accurately.
Translates medical probability and statistical literacy into clear clinical decision-making using natural frequencies rather than confusing percentages. Demonstrates how doctors and patients frequently misread screening sensitivity, false positives, and lifestyle risk reductions.
Distilling their celebrated Lancet epidemiology series, CONSORT co-author Kenneth Schulz and David Grimes clarify allocation concealment, selection bias, multiplicity pitfalls, and non-inferiority trials with lucid clinical examples.
Synthesizes decades of Whitehall cohort research to prove how socioeconomic status, early childhood conditions, and workplace autonomy drive chronic disease gradients. Connects upstream social determinants directly to physiological stress pathways and preventable mortality.
Written by a vaccine expert, this book provides an inside look at the unprecedented effort to develop COVID-19 vaccines at remarkable speed. It explains the science behind the vaccines and the logistical and regulatory hurdles involved. is essential for understanding a key contemporary topic of the pandemic – the vaccine development and rollout. It valuable resource for students interested in vaccinology and public health interventions.
Maps modifiable behavioral, metabolic, and environmental risk factors onto actionable health policy levers in the post-COVID era. Shows public health practitioners how primary care reform, insurance incentives, and structural interventions curb preventable chronic disease.
Fourth-edition updates by Johns Hopkins and Harvard biostatistician Steven Piantadosi provide deep quantitative rigor on Phase I dose-finding designs, competing risks, factorial trials, and translational biomarker endpoints.
Articulates the ecosocial theory of disease distribution, examining how biological exposures, ecological context, and structural inequities become physically embodied as health risk. Updated for 2024 to help researchers move beyond narrow biomedical risk checklists.
Fayers and Bee Choo Tai bridge pragmatic trial operations with statistical reporting, covering cluster-randomized trials, quality-of-life patient-reported outcomes, missing data imputation, and CONSORT compliance.
Provides a comprehensive overview of various aspects of patient outcomes, including measurement, analysis, and the impact of health interventions. Suitable for healthcare professionals seeking to improve patient care and outcomes.
Investigates the controversial topic of the origins of SARS-CoV-2, exploring both natural spillover and laboratory leak hypotheses. It dives into contemporary scientific and political debates surrounding the pandemic's beginning, offering a deeper understanding of this ongoing discussion. This book is valuable for advanced students and professionals interested in the scientific investigation and the challenges of determining the source of a novel virus. It presents a detailed analysis of the available evidence.
Bridges potential-outcomes causal inference with social epidemiology to evaluate complex population-level risk factors. Equips advanced researchers to test policy and social interventions rigorously without sacrificing real-world public health validity.
Provides a comprehensive overview of the different types of antibiotics and their mechanisms of action. It also discusses the clinical uses of antibiotics and the development of antibiotic resistance. The book is written in a clear and concise style and is suitable for students and professionals in the field of infectious diseases.
Comprehensive textbook on antimicrobial chemotherapy. It provides detailed information on the different types of antibiotics, their mechanisms of action, and their clinical uses. The book also discusses the development of antibiotic resistance and the challenges of antibiotic discovery.
Provides a comprehensive overview of the use of antibiotics in clinical practice. It discusses the different types of antibiotics, their mechanisms of action, and their clinical uses. The book also discusses the development of antibiotic resistance and the importance of antibiotic stewardship.
Provides a comprehensive overview of antibiotics and bacterial resistance. It discusses the different types of antibiotics, their mechanisms of action, and their clinical uses. The book also discusses the development of antibiotic resistance and the challenges of antibiotic discovery.
Comprehensive guide to antibiotics. It provides detailed information on the different types of antibiotics, their mechanisms of action, and their clinical uses. The book also discusses the development of antibiotic resistance and the importance of antibiotic stewardship.
Scott Gottlieb, former FDA commissioner, offers a detailed analysis of the US response to COVID-19, examining the systemic failures and offering recommendations for the future. provides an informed perspective on the policy and regulatory challenges of a pandemic. It valuable resource for understanding the intricacies of public health decision-making during a crisis. It offers a contemporary and critical look at the US experience.
Delivers the quintessential Johns Hopkins introduction to measuring disease frequency, cohort and case-control risk estimation, and screening evaluation. Updated in its seventh edition to ground medical and public health learners in odds ratios, attributable risk, and causal reasoning.
Underpowered clinical trials waste patient lives and research funding. Chow, Shao, Wang, and Lokhnygina provide exact power and sample-size formulas for superiority, equivalence, adaptive, and bioequivalence designs.
Pharmaceutical biostatisticians and clinical data programmers rely on Walker and Shostak to execute analysis of covariance, Kaplan-Meier survival curves, Cox proportional hazards, and categorical exact tests in SAS.
Debora MacKenzie, a science journalist, provides an early and insightful account of the COVID-19 pandemic, arguing that it was preventable. The book examines the missed opportunities and systemic failures that contributed to the global spread of the virus. It offers a critical perspective on the initial response and lessons for the future. is valuable for understanding the early dynamics of the pandemic and the public health challenges involved.
Offers a critical look at the public health response to COVID-19 in the United States, highlighting systemic failures and political challenges. It provides valuable insights into the complexities of managing a pandemic at a national level and the factors that can hinder an effective response. This book is particularly relevant for those interested in public health policy and administration. It offers a contemporary perspective on the handling of the pandemic.
Examines preventive medicine through the four major chronic disease risk clusters: atherosclerotic cardiovascular disease, cancer, neurodegeneration, and metabolic dysfunction. Translates biomarker tracking, apoB lipidology, and lifestyle interventions into proactive risk reduction.
Presents a rigorous yet practical framework for isolating true causal effects of medical and behavioral exposures from observational data. Covers target trial emulation, directed acyclic graphs, inverse probability weighting, and time-varying confounding.
Operationalizing ICH E6(R2/R3) Good Clinical Practice in the field, Woodin and Schneider train Clinical Research Associates in source document verification, risk-based monitoring, informed consent audits, and serious adverse event reporting.
The editor-in-chief of The Lancet offers a critical analysis of the global response to the COVID-19 pandemic, arguing that many failures were avoidable. provides a contemporary and expert perspective on the systemic issues that contributed to the catastrophe. It is valuable for advanced students and professionals interested in global health governance and pandemic preparedness at an international level.
Compiles authoritative empirical evidence on how neighborhood deprivation, income inequality, discrimination, and social networks shape disease incidence. Essential reading for researchers modeling multi-level psychosocial and structural health risk factors.
Renowned biostatistician Stephen Senn analyzes AB/BA and Latin-square crossover designs, washout period carryover effects, and within-patient variance reduction in chronic disease trials.
Applies the 'One Health' approach, which recognizes the interconnectedness of human, animal, and environmental health, to the COVID-19 pandemic. It explores the origins and spread of the virus through this integrated lens, offering insights into preventing future outbreaks. This valuable resource for understanding the complex ecological and political factors influencing pandemics. It is relevant for students in public health, veterinary medicine, and environmental studies.
Harry Yang and Liang Zhao examine decentralized trial architectures, real-world evidence integration, AI-assisted patient recruitment, and Bayesian adaptive designs transforming contemporary drug development.
Focuses on how the COVID-19 pandemic exposed and exacerbated existing health inequalities based on factors like socioeconomic status, race, and geography. It provides a critical analysis of the disproportionate impact of the virus on vulnerable populations. This is essential reading for those interested in the social determinants of health and health equity in the context of a pandemic. It offers a contemporary perspective on a crucial aspect of the COVID-19 crisis.
Bill Gates outlines his vision for preventing future pandemics, drawing lessons from COVID-19 and his work in global health. offers a forward-looking perspective on global health security and the necessary investments and strategies to mitigate future threats. It is relevant for anyone interested in the future of public health and global cooperation. The book provides a high-level overview of potential solutions and is accessible to a broad audience.
Written by a sociologist and physician, this book examines the multifaceted impact of COVID-19 on society, covering not only the biological aspects but also the social, psychological, and economic consequences. It provides a broad understanding of how the pandemic has affected various aspects of human life. is relevant for students across disciplines seeking to understand the wider implications of the pandemic.
Details the specialized statistical and study-design methods needed to link dietary exposures to chronic disease risk without measurement distortion. Covers food-frequency validation, caloric adjustment, biochemical markers, and longitudinal cohort analysis.
Group-sequential stopping rules, sample-size re-estimation, and seamless Phase II/III pick-the-winner platform trials accelerate drug development when backed by Mark Chang's Monte Carlo operating characteristic simulations.
Connects disease biology directly to population-level prevention policy, tracing how infectious, environmental, and behavioral risk factors translate into morbidity. Written by a former New York City health commissioner for applied public health curricula.
Guides biostatisticians and clinical researchers through developing, calibrating, and externally validating multivariable disease risk scores. Addresses predictor selection, overfitting, missing values, and decision-curve evaluation for clinical prognosis.
Providing a practical site-level reference for study coordinators and research nurses, Norris covers investigator site files, case report form completion, investigational product accountability, and FDA audit readiness.
Sharpens critical appraisal of health risk headlines by exposing cherry-picked observational studies, publication bias, and relative-risk exaggeration. Offers an entertaining interdisciplinary defense against statistical pseudoscience in public health reporting.
Equips public health learners with the core quantitative machinery behind risk factor inference, from confidence intervals and contingency tables to logistic regression and survival analysis. Grounds every statistical formula in real epidemiological datasets.
Focuses on patient outcomes in cancer care, covering topics such as quality of life, functional outcomes, and survivorship. It provides valuable insights for healthcare professionals involved in cancer treatment and research.
Delves into the mathematical and scientific principles behind how outbreaks spread, not just biologically but also in terms of information and behavior. It provides a deeper understanding of the mechanisms driving the COVID-19 pandemic and the factors that influence its trajectory. This is particularly useful for students interested in the quantitative aspects of infectious disease transmission and public health interventions. It is considered a valuable resource for understanding the science of contagion.
Co-authored by Cochrane Collaboration founder Sir Iain Chalmers, Imogen Evans, Hazel Thornton, and Paul Glasziou, this vivid narrative illustrates why unblinded clinical intuition repeatedly harms patients until tested in fair trials.
History of the development and use of antibiotics. It traces the history of antibiotics from their discovery in the early 20th century to their widespread use in the mid-20th century. The book also discusses the development of antibiotic resistance and the challenges of antibiotic discovery in the 21st century.
For more information about how these books relate to this course, visit:
OpenCourser.com/career/u10bhk/medical
Save
